Following its successful re-entry into the German patents scene (2012), this respected practice has now raised its associate headcount. Young Düsseldorf litigator Cepl is increasingly visible, as is veteran Feldges in central pharmaceuticals battles, e.g. for regular client Pfizer in injunction proceedings involving the drug Lyrica. The latter also boasts an excellent reputation for arbitration related to IP. Having regained strength in Germany, the European patents team is well set for the launch of the UPC system, with its expertise in London and Paris.
Litigation related to biotech and pharmaceuticals patents; arbitration.
The German patents team’s low visibility in mobile communications suits remains an obstacle if A&O wants to play a central role in the UPC. Cepl’s gradual development efforts, or reinforcement from a lateral with experience here, are two possible solutions.
Dr. Joachim Feldges, Dr. Philipp Cepl.
1 partner, 4 associates
Broad IP activity with expertise in technical protection rights. Exclusively opposition and nullity suits and infringement proceedings with a strong specialty in biotech and pharmaceuticals. Also electronics and mechanics. Arbitration, transactions, strategic advice and licensing.
Pfizer in injunction proceedings regarding Lyrica; Borealis and Uber in connection with infringement proceedings; litigation for Hoffmann-La Roche; arbitration for turbine manufacturer.